# American Gene Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/american-gene-technologies

- Industry: Biotechnology
- Headquarters: Rockville, US
- Website: www.americangene.com
- Total disclosed funding: $25M
- Latest round: Series B (Jan 21, 2025)
- Investors on record: 1

## About

Founded in 2007 and based in Maryland, US, American Gene Technologies Inc. operates as a clinical-stage biotechnology company that provides gene and cell therapy for diseases like cancer and the human immunodeficiency virus (HIV). As of 2022, Jeff Galvin is the founder and CEO of the company. In April 2022, American Gene Technologies, Inc. raised angel funding from Ride Wave.

The company is developing genetic therapies to treat significant diseases such as HIV, PKU, and hepatocellular carcinoma (also known as liver cancer, or HCC). The company offers the American Gene™ delivery platform, which speeds up the development of a wide range of medication candidates.

The company's pipeline includes AGT-103-T, an HIV treatment in Phase 1 clinical trials, and AGT-CS168, which collects venous blood specimens from HIV patients. American Gene's technology includes drug development, genetic technology, and immunotox - gamma delta T cell cancer therapy.

The organization plans to use the April 2022 funding to further develop its gene therapies.

## Funding rounds

- Series B, Jan 21, 2025, $15M — Carat Venture Partners
- Series B, Dec 10, 2024, $10M — Carat Venture Partners

## Investors

- Carat Venture Partners (https://capitalatlas.ai/funds/carat-venture-partners) — Series B